FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362678077> ?p ?o ?g. }

• W4362678077 endingPage "101180" @default.
• W4362678077 startingPage "101180" @default.
• W4362678077 abstract "Adjuvant management of borderline ovarian tumors (BOT) after surgical diagnosis and staging is not standardized. While many patients undergo observation alone, some providers have introduced the use of adjuvant antihormonal therapy for BOT, extrapolating from studies suggesting improvement in progression-free survival in the low-grade serous ovarian carcinoma population. We hypothesized that adjuvant antihormonal therapy after surgical diagnosis of BOT would improve progression-free survival compared to surveillance alone. This is a retrospective review of BOT at one academic institution over thirteen years comparing management with antihormonal therapy, including aromatase inhibitors, progestins, and selective estrogen receptor modulators, to surveillance alone. Patients with concurrent malignancy were excluded. Data were abstracted from electronic medical records. Groups were compared by bivariate statistics. We identified 193 patients with BOT. Of these, 17 (8.8%) were treated with adjuvant antihormonal therapy and 24 (12.4%) recurred. Patients treated with antihormonal therapy were more likely to be obese (64.7% vs 37.9%, p = 0.032), have advanced-stage disease (70.6% vs 11.4%, p < 0.001), serous histotype (94.1% vs 59.4%, p = 0.005) or microinvasion (29.4% vs 9.7%, p = 0.030), and less likely to have undergone fertility-sparing surgery (18.8% vs 51.7%, p = 0.012). Use of antihormonal therapy was not associated with a difference in recurrence or survival. This study is the first retrospective cohort review of adjuvant antihormonal therapy in BOT. We found that adjuvant antihormonal therapy for BOT is not associated with recurrence. While this single institution retrospective cohort study may lack the power to confirm or refute benefit, further studies could evaluate whether a subpopulation exists in whom antihormonal therapy is worthwhile." @default.
• W4362678077 created "2023-04-07" @default.
• W4362678077 creator A5005688710 @default.
• W4362678077 creator A5035109058 @default.
• W4362678077 creator A5054055388 @default.
• W4362678077 creator A5071984875 @default.
• W4362678077 date "2023-06-01" @default.
• W4362678077 modified "2023-10-01" @default.
• W4362678077 title "The impact of adjuvant antihormonal therapy versus observation on recurrence of borderline ovarian tumors: A retrospective cohort study" @default.
• W4362678077 cites W1978739936 @default.
• W4362678077 cites W1992361486 @default.
• W4362678077 cites W2014463690 @default.
• W4362678077 cites W2028730470 @default.
• W4362678077 cites W2053292861 @default.
• W4362678077 cites W2107229975 @default.
• W4362678077 cites W2114903993 @default.
• W4362678077 cites W2145480209 @default.
• W4362678077 cites W2250463341 @default.
• W4362678077 cites W2298821226 @default.
• W4362678077 cites W2343517882 @default.
• W4362678077 cites W2590528754 @default.
• W4362678077 cites W2947475988 @default.
• W4362678077 cites W2979676019 @default.
• W4362678077 cites W3109956557 @default.
• W4362678077 cites W3138979031 @default.
• W4362678077 doi "https://doi.org/10.1016/j.gore.2023.101180" @default.
• W4362678077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37096018" @default.
• W4362678077 hasPublicationYear "2023" @default.
• W4362678077 type Work @default.
• W4362678077 citedByCount "0" @default.
• W4362678077 crossrefType "journal-article" @default.
• W4362678077 hasAuthorship W4362678077A5005688710 @default.
• W4362678077 hasAuthorship W4362678077A5035109058 @default.
• W4362678077 hasAuthorship W4362678077A5054055388 @default.
• W4362678077 hasAuthorship W4362678077A5071984875 @default.
• W4362678077 hasBestOaLocation W43626780771 @default.
• W4362678077 hasConcept C121608353 @default.
• W4362678077 hasConcept C126322002 @default.
• W4362678077 hasConcept C143998085 @default.
• W4362678077 hasConcept C150173356 @default.
• W4362678077 hasConcept C167135981 @default.
• W4362678077 hasConcept C2777863537 @default.
• W4362678077 hasConcept C2777982462 @default.
• W4362678077 hasConcept C2908647359 @default.
• W4362678077 hasConcept C71924100 @default.
• W4362678077 hasConcept C72563966 @default.
• W4362678077 hasConcept C99454951 @default.
• W4362678077 hasConceptScore W4362678077C121608353 @default.
• W4362678077 hasConceptScore W4362678077C126322002 @default.
• W4362678077 hasConceptScore W4362678077C143998085 @default.
• W4362678077 hasConceptScore W4362678077C150173356 @default.
• W4362678077 hasConceptScore W4362678077C167135981 @default.
• W4362678077 hasConceptScore W4362678077C2777863537 @default.
• W4362678077 hasConceptScore W4362678077C2777982462 @default.
• W4362678077 hasConceptScore W4362678077C2908647359 @default.
• W4362678077 hasConceptScore W4362678077C71924100 @default.
• W4362678077 hasConceptScore W4362678077C72563966 @default.
• W4362678077 hasConceptScore W4362678077C99454951 @default.
• W4362678077 hasLocation W43626780771 @default.
• W4362678077 hasLocation W43626780772 @default.
• W4362678077 hasLocation W43626780773 @default.
• W4362678077 hasOpenAccess W4362678077 @default.
• W4362678077 hasPrimaryLocation W43626780771 @default.
• W4362678077 hasRelatedWork W1568071278 @default.
• W4362678077 hasRelatedWork W2029712100 @default.
• W4362678077 hasRelatedWork W2051447115 @default.
• W4362678077 hasRelatedWork W2054423421 @default.
• W4362678077 hasRelatedWork W2075088688 @default.
• W4362678077 hasRelatedWork W2096393323 @default.
• W4362678077 hasRelatedWork W2414195948 @default.
• W4362678077 hasRelatedWork W2623400261 @default.
• W4362678077 hasRelatedWork W2897782746 @default.
• W4362678077 hasRelatedWork W4367319693 @default.
• W4362678077 hasVolume "47" @default.
• W4362678077 isParatext "false" @default.
• W4362678077 isRetracted "false" @default.
• W4362678077 workType "article" @default.